International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia.

"Competing Interests G.F.W. has received honoraria related to consulting, research and/or speaker activities from Amgen, Arrowhead, AstraZeneca, CRISPR Therapeutics, Esperion, Novartis and Sanofi. L.K.J. is a consultant for Novartis. M.N.S. has received personal fees from Amgen. J.P. has received grants from the National Health and Medical Research Council (NHMRC, Australia), the Medical Research Future Fund (MRRF, Australia), the Department of Health of Western Australia and the Royal Perth Hospital Research Foundation. S.S.G. is a consultant for Esperion and on a scientific advisory panel for Silence Therapeutics. P.L. has received research funding from Novartis; is on the Board of Directors of XBiotech; has a financial interest in Soley Therapeutics, TenSixteen Bio and XBiotech; is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer and Sanofi-Regeneron; is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Moderna, Novartis, PlaqueTec, Soley Thereapeutics, TenSixteen Bio and XBiotech. R.D.S. has received honoraria related to consulting, research and/or speaker activities from Abbott, Ache, Amgen, AstraZeneca, EMS, Esperion, GETZ Pharma, Kowa, Libbs, Novartis, Novo-Nordisk, Merck, MSD, Pfizer, PTC Therapeutics and Sanofi/Regeneron."

"G.F.W. has received honoraria related to consulting, research and/or speaker activities from Amgen, Arrowhead, AstraZeneca, CRISPR Therapeutics, Esperion, Novartis and Sanofi. L.K.J. is a consultant for Novartis. M.N.S. has received personal fees from Amgen. J.P. has received grants from the National Health and Medical Research Council (NHMRC, Australia), the Medical Research Future Fund (MRRF, Australia), the Department of Health of Western Australia and the Royal Perth Hospital Research Foundation. S.S.G. is a consultant for Esperion and on a scientific advisory panel for Silence Therapeutics. P.L. has received research funding from Novartis; is on the Board of Directors of XBiotech; has a financial interest in Soley Therapeutics, TenSixteen Bio and XBiotech; is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer and Sanofi-Regeneron; is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Moderna, Novartis, PlaqueTec, Soley Thereapeutics, TenSixteen Bio and XBiotech. R.D.S. has received honoraria related to consulting, research and/or speaker activities from Abbott, Ache, Amgen, AstraZeneca, EMS, Esperion, GETZ Pharma, Kowa, Libbs, Novartis, Novo-Nordisk, Merck, MSD, Pfizer, PTC Therapeutics and Sanofi/Regeneron."